Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W0MW | ISIN: US69366J2006 | Ticker-Symbol: BH3
Tradegate
20.11.24
15:35 Uhr
37,800 Euro
-2,000
-5,03 %
1-Jahres-Chart
PTC THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PTC THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
39,40040,40013:13
39,60040,40013:15

Aktuelle News zur PTC THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrFDA Approves PTC's Kebilidi As First Gene Therapy To Treat AADC Deficiency2
14.11.PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain1
14.11.FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain1
14.11.PTC wins FDA approval for first brain-delivered gene therapy Kebilidi1
PTC THERAPEUTICS Aktie jetzt für 0€ handeln
14.11.PTC wins US approval of gene therapy for fatal enzyme disorder4
14.11.FDA grants accelerated approval for PTC's AADC deficiency gene therapy1
14.11.PTC Therapeutics wins FDA nod for gene therapy2
14.11.PTC gets FDA okay for first brain-delivered gene therapy-
14.11.US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder1
14.11.PTC Therapeutics, Inc.: PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy88- First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children and adults - -...
► Artikel lesen
08.11.PTC Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary2
07.11.PTC Therapeutics, Inc.: PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results37- Strong revenue performance, supporting increase in full-year revenue guidance to $750 -800 million - - Regulatory filings for sepiapterin, Translarna and AADC...
► Artikel lesen
07.11.PTC THERAPEUTICS, INC. - 10-Q, Quarterly Report-
07.11.PTC THERAPEUTICS, INC. - 8-K, Current Report-
07.11.PTCT-Aktie erreicht 52-Wochen-Hoch bei 43,41 US-Dollar1
06.11.Earnings Preview For PTC Therapeutics3
30.10.PTC Therapeutics resubmitted NDA for Translarna accepted by FDA1
30.10.FDA reviews PTC's Duchenne drug application2
30.10.PTC Therapeutics, Inc.: PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission232WARREN, N.J., Oct. 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) has accepted for...
► Artikel lesen
25.10.PTC Therapeutics, Inc.: PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)113WARREN, N.J., Oct. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2024, the company approved non-statutory stock...
► Artikel lesen
Seite:  Weiter >>
96 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1